Ibrutinib vs Pirtobrutinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Lymphocytic Leukemia

Shared mechanism: BTK · full Chronic Lymphocytic Leukemia pipeline

Ibrutinib

Marketed by AbbVie and partners

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT01578707 · Phase 3 · completed

This was a large randomized, active-controlled trial of ibrutinib versus ofatumumab, with progression-free survival as a clinical primary endpoint and a statistically significant favorable result for ibrutinib. However, treatment was open-label rather than double-blinded, so the evidence is graded moderate despite the strong primary result.

Next expected readout: December 2026 · NCT03513562 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to 5 years): Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) (met)

Result source: NCT01611090

Pirtobrutinib

Marketed by Eli Lilly

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT04666038 · Phase 3 · active, not recruiting

Patients were randomised 1:1 against active standard options and the primary endpoint, independently assessed progression-free survival, was met (hazard ratio 0.536, p=0.0002) in 238 patients. The trial was open-label, so patients and clinicians knew the assigned treatment, and the comparator was a mix of two regimens with crossover allowed after progression.

Next expected readout: December 2026 · NCT06466122 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Arm A - Pirtobrutinib 13.96 Months (95% CI 11.24 to 16.56) | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab 8.74 Months (95% CI 8.08 to 10.38) (met)

Result source: NCT04666038

Results for Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pirtobrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ibrutinib
Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) NCT01611090 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ibrutinib's landscape · Pirtobrutinib's landscape